Webflow is an AI-native Website Experience Platform that empowers teams to visually build, manage, and optimize websites that offer both the consumer experience customers expect and the enterprise-grade performance and scale they need. Webflow aims to give users full control over their websites without reliance on engineering, with big-name customers including NCR, Dropbox, Spotify and DocuSign.Linda Tong, the CEO of Webflow, explains why she sees the web actively splitting into two versions - one for us and one for AI bots, and how companies are adapting and will continue to adapt to maintain traffic to their websites. Linda speaks with Carol Massar and Tim Stenovec on Bloomberg Businessweek Daily.See omnystudio.com/listener for privacy information.
--------
7:07
--------
7:07
Bloomberg Businessweek Weekend: November 14th, 2025
Featuring some of our favorite conversations of the week from our daily radio show “Bloomberg Businessweek Daily.” Hosted by Carol Massar and Tim Stenovec Hear the show live at 2PM ET on WBBR 1130 AM New York, Bloomberg 92.9 FM Boston, WDCH 99.1 FM in Washington D.C. Metro, Sirius/XM channel 121, on the Bloomberg Business App, Radio.com, the iHeartRadio app and at Bloomberg.com/audio. You can also watch Bloomberg Businessweek on YouTube - just search for Bloomberg Global News. Like us at Bloomberg Radio on Facebook and follow us on Twitter @carolmassar @timsteno and @BWSee omnystudio.com/listener for privacy information.
--------
1:27:29
--------
1:27:29
Massachusetts Making Push to Offset Trump’s Research Cuts
Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF.Business leaders, investors and academics have cheered Massachusetts Governor Maura Healey’s efforts to counter the Trump administration’s research funding cuts with state money — so much so that a recent meeting on the initiative required overflow seating. Healey, a Democrat, in July proposed funneling $400 million to institutions affected by the federal pullback. Half of the money in Healey’s proposal would come from revenue raised by the state’s millionaire’s tax and would be reserved for the University of Massachusetts and other public colleges, while the rest could go to hospitals and private schools such as Harvard University.She’s also seeking to establish a separate fund with contributions from philanthropists and private investors. The funds are meant to be a Band-Aid to help protect the universities and medical organizations that form the backbone of the Massachusetts economy. Healey sees the bill not only as a lifeline for life-saving therapies, but also as a way to retain the research talent that’s made Boston a global hub for the health-care industry.Today's show features interviews conducted during a special broadcast from Boston Children's Hospital: Bloomberg News Boston Money and Power Reporter Greg Ryan on a Massachusetts proposal to funnel $400 million to institutions affected by the federal pullback in research funding, Boston’s biotech real estate slump and other key regional issues Dr. Joan LaRovere, Chief Medical Officer of Boston Children’s Hospital, on why research and innovation are central priorities for the nation’s leading medical institutions Dr. Lissa Baird, Director of Neurosurgical Oncology and Co-director of the Brain Tumor Center at Boston Children’s Hospital, on leading one of the world’s most advanced pediatric neurosurgery programs Dr. Ellen Grant, Director of Fetal-Neonatal Neuroimaging and Developmental Science at Boston Children’s Hospital, on the unmet needs to help treat women’s neurological health issues from migraines to autoimmune disorders to perinatal mental wellness Dr. Martha Murray, Orthopedic Surgeon-in-Chief for Boston Children’s Hospital, on how she helped transform the treatment of ACL tears by pioneering an innovative, FDA-approved surgical procedure that promotes a more natural healing of ligament tears, an injury most common in teen girls and young women See omnystudio.com/listener for privacy information.
--------
49:00
--------
49:00
Bitcoin Sinks Deeper Below $100,000 as Bear Market Grips Crypto
Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF.Bitcoin sank deeper below the $100,000 mark, dragged down by a fresh wave of risk aversion and a selloff in tech stocks that reignited Wall Street jitters.The digital currency fell as much as 3.9% to $97,956, intensifying a slump that’s wiped out more than $450 billion in value since early October. Once-reliable sources of support — including large investment funds, ETF allocators, and corporate treasuries — have stepped back, removing a key prop from this year’s rally and triggering a new phase of market fragility.Analysts at 10x Research say the crypto market has entered a confirmed bear regime. The firm cites weakening ETF flows, continuing selling by long-term holders, and muted participation from retail buyers. The firm’s models flagged the shift in mid-October and now point to deteriorating sentiment beneath the surface. The next key level is $93,000, according to 10x.Today's show features: Eric Trump, Co-Founder and Chief Strategy Officer of American Bitcoin, on his company’s business model and the regulatory environment for cryptocurrency Elizabeth Renter, Senior Economist at NerdWallet, on key economic data expectations as the US government reopens Bloomberg Intelligence Senior Media Analyst Geetha Ranganathan breaks down quarterly earnings from Disney See omnystudio.com/listener for privacy information.
--------
36:24
--------
36:24
FDA Pulls Warning Labels From Hormone Replacement Therapies
Hormone replacement therapies (HRTs) used to treat menopause symptoms no longer need to carry strict warnings about some potential side effects, including cancer and heart disease, the US Food and Drug Administration announced Monday. Commissioner Marty Makary said the agency is asking drugmakers to remove the strict black box warnings, with the goal of encouraging more women to take them. Labels on the medicines currently list potential side effects including cardiovascular disease, blood clots, breast cancer and dementia. Fanny Elahi, MD, PhD is a physician-scientist and Associate Professor in the Departments of Neurology, Neuroscience, and Pathology at the Icahn School of Medicine at Mount Sinai in New York City. Dr. Elahi discusses the implications of this move and the importance of such therapies, particularly for women approaching menopause, with Carol Massar and Tim Stenovec on Bloomberg Businessweek Daily.See omnystudio.com/listener for privacy information.
Carol Massar and Tim Stenovec bring you reporting from the magazine that helps global leaders stay ahead, plus insight on the people, companies and trends shaping today's complex economy. Watch us LIVE on YouTube: http://bit.ly/3vTiACF.
USA